Why Shares in Novo Nordisk Soared This Week

Novo Nordisk (NYSE: NVO) shares surged by 12.7% in the week to Friday morning as investors received positive news on an orally administered weight loss drug pivotal to the company's future.With Novo Nordisk's Wegovy (semaglutide) seen as losing market share in the subcutaneous (injectable) weight loss drug market to Eli Lilly's Zepbound, the race is on to commercialize an orally administered drug, not least because an oral version will have significant convenience advantages over an injectable one.That said, there are challenges involved in producing an orally administered weight loss drug, including the usual issues of demonstrating efficacy, as well as safety and tolerability. The good news is that Novo Nordisk's orally administered Wegovy (semaglutide) appears to be ahead of the field of GLP-1 drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool